Clinuvel Pharmaceuticals Limited announced that Mr. Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr. Willem Blijdorp has been elected Chair and will take on the role on 30 November 2019. Mr. Blijdorp joined the CLINUVEL Board as a Non-Executive Director in 2015. He is an internationally recognised entrepreneur who has founded and expanded the B&S Group. Mr. Blijdorp originally positioned B&S as a Dutch trading and shipping group active in Duty Free, and subsequently grew the Group to a wholesale and international trading house of luxury and fast-moving consumer goods; now a leader in its market sector. He led and oversaw the Group's initial public offering on Euronext Amsterdam in March 2018. Mr. McLiesh joined the CLINUVEL Board in 2002 and was elected Chair in 2010, guiding the Company through the research and development phase, the regulatory path and the commercialisation of SCENESSE® (afamelanotide 16mg) for the treatment of adults with the rare genetic disorder, erythropoietic protoporphyria (EPP).